Last reviewed · How we verify
Standard-dose rtPA
Standard-dose rtPA works by dissolving blood clots to restore blood flow to the brain.
Standard-dose rtPA is a thrombolytic agent used primarily for acute ischemic stroke. Despite no FDA label, it is widely studied in various phases of clinical trials, including nebulized administration for ARDS due to COVID-19 and combination therapies. Key trials include ENCHANTED and the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis.
At a glance
| Generic name | Standard-dose rtPA |
|---|---|
| Also known as | Actilyse |
| Sponsor | The George Institute |
| Drug class | Thrombolytic |
| Target | tPA |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Standard-dose rtPA is a thrombolytic agent that specifically targets plasminogen activator, which breaks down blood clots. This process helps to restore blood flow to the brain, reducing the risk of further brain damage and improving outcomes in patients with acute ischemic stroke.
Approved indications
- Acute ischemic stroke
Common side effects
- Hemorrhage
- Allergic reactions
- Fever
- Headache
- Nausea
- Vomiting
- Dizziness
- Fatigue
- Pain or discomfort